Larotrectinib, Xofigo, Copanlisib, & Regorafenib Research

Scott Fields, SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Larotrectinib, Xofigo, Copanlisib, & Regorafenib Research. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.